Cancer epigenetics in clinical practice

V Davalos, M Esteller - CA: a cancer journal for clinicians, 2023 - Wiley Online Library
Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

SN Lone, S Nisar, T Masoodi, M Singh, A Rizwan… - Molecular cancer, 2022 - Springer
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

Non‐small cell lung cancer in China

P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Circulating tumor cells: biology and clinical significance

D Lin, L Shen, M Luo, K Zhang, J Li, Q Yang… - Signal transduction and …, 2021 - nature.com
Circulating tumor cells (CTCs) are tumor cells that have sloughed off the primary tumor and
extravasate into and circulate in the blood. Understanding of the metastatic cascade of CTCs …

[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J Pascual, G Attard, FC Bidard, G Curigliano… - Annals of …, 2022 - Elsevier
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Evaluation of cell-free DNA approaches for multi-cancer early detection

A Jamshidi, MC Liu, EA Klein, O Venn, E Hubbell… - Cancer Cell, 2022 - cell.com
Summary In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

P Stejskal, H Goodarzi, J Srovnal, M Hajdúch… - Molecular cancer, 2023 - Springer
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

[HTML][HTML] Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

EA Klein, D Richards, A Cohn, M Tummala… - Annals of …, 2021 - Elsevier
Background A multi-cancer early detection (MCED) test used to complement existing
screening could increase the number of cancers detected through population screening …

Liquid biopsy enters the clinic—implementation issues and future challenges

M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Liquid biopsies: the future of cancer early detection

S Connal, JM Cameron, A Sala, PM Brennan… - Journal of translational …, 2023 - Springer
Cancer is a worldwide pandemic. The burden it imposes grows steadily on a global scale
causing emotional, physical, and financial strains on individuals, families, and health care …